Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders; PharmaOS, a pharmaceutical digital marketing platform; and Enterprise-Medical Academic Interaction Platform, an enterprise-medical communication. It also provides software solutions, such as eCollect, an electronic data capture system; eCooperate, a clinical trial project management system; eBalance, a supply manage system; eArchives, a clinical trial document management system; and eCollege, a training management system; and eklmage medical imaging evalution system, EMS site management system, and paylite financial management system. In addition, the company offers trial partner digital SMO services, IRC independent review center solution, eSAE clinical trial safety information management system; eSite Pro clinical trial management platform, eTrialPro research ward management system, GCP-X intelligent clinical trial platform, IIT-EDC research data collection system; eMonitoring(iRMS) intelligent remote monitoring system, IDS investigational drug services; iDCT intelligent decentralized clinical trial; eScreening subject information management system; eSafety Pharmacovigilance Compliance Management System, eSAE Clinical Trial Safety Information Management System; ONECEM-SFE Sales Force Effectiveness, ONECEM-SCRM Intelligent Marketing System, ONECEM-Event+Engagement; and ONEInsight Marketing Data Platform. Zhejiang Taimei Medical Technology Co., Ltd.was founded in 2013 and is headquartered in Jiaxing, China.
Metrics to compare | 2576 | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship Relationship2576PeersSector | |
---|---|---|---|---|
P/E Ratio | −11.6x | 4.2x | −0.5x | |
PEG Ratio | −0.27 | 0.24 | 0.00 | |
Price/Book | - | 2.7x | 2.6x | |
Price / LTM Sales | 4.5x | 6.4x | 3.3x | |
Upside (Analyst Target) | 45.8% | 2.3% | 43.5% | |
Fair Value Upside | Unlock | −4.8% | 6.9% | Unlock |